WASHINGTON – A federal panel of medical experts said last week a first-of-a-kind imaging chemical designed to help screen for Alzheimer’s disease could be useful pending additional study and training for physicians.
The Food and Drug Administration panel of advisers voted 16-0 in favor of approval for Eli Lilly’s Amyvid on the condition that the company demonstrate that the images can be interpreted consistently by physicians who have received training in reading the scans.
Without those requirements, the panel voted 13-3 against approval for the injection in an earlier vote. The FDA is not required to follow the panel’s advice, although it often does.
Amyvid is an experimental injection designed to highlight brain plaque in medical imaging scans. While panelists said the chemical helped improve visibility of the plaque, they were concerned about the widely different interpretations when doctors examined the brain scans. Panelists worried about disparate results and incorrect diagnoses in the hands of thousands of doctors across the United States.
Alzheimer’s affects 5 million elderly people in the United States and will take an even greater toll as baby boomers move into old age. The disease attacks neurons in the brain, leading to problems with memory, thinking and behavior. There is no cure for the disease, and scientists are not even sure what causes it.
Doctors currently diagnose the disease by observing patients and administering physical and mental tests. Researchers have argued that spotting amyloid plaque could yield earlier detection.
Amyvid, known generically as florbetapir, is an imaging agent injected into patients who are then put through a positron emission tomography, or PET, scan to detect the plaque. Eli Lilly’s research suggests that a negative test for the plaque helps to rule out Alzheimer’s disease.
Eli Lilly and Co. paid $300 million last year to acquire the drug and its developer, Avid Radiopharmaceuticals Inc.
Like many drug makers, Lilly, based in Indianapolis, Indiana, faces a wave of patent expirations in coming years that will dramatically shrink its revenue. Its top-selling product, the schizophrenia drug Zyprexa, loses patent protection this year, exposing more than $4 billion in annual sales to generic competition. The patent on the company’s second best-seller, the antidepressant Cymbalta, loses protection in the next few years.
Company shares fell 15 cents to $34.50 in after-hours trading.
Associated Press
